The American Society of Clinical Oncology (ASCO) has fully updated its antiemetic guideline for patients with cancer receiving chemotherapy and radiation therapy for the first time since 2015. The ...

Zyprexa addition to standard antiemetics significantly reduces RINV incidence and severity in abdominal/pelvic radiotherapy patients. The trial showed marked improvements in nausea, vomiting, anxiety, ...

In this small breast cancer–dedicated solo practice, a retrospective medical record review disclosed the following: significant rate of chemotherapy-related nausea and vomiting and discordance between ...

Am J Health Syst Pharm. 2007;64(21):2227-2236. A recent study found an increased incidence of CHF in older women who had more than 10 years of follow-up and were treated with adjuvant anthracyclines. ...

Researchers from Japan found that a 5 mg dose of olanzapine, taken after chemotherapy, significantly reduces nausea and vomiting in breast cancer patients, while minimizing sedation and cutting costs.

Palliative care referral and utilization patterns among patients diagnosed with metastatic lung cancer within an urban safety-net hospital system.

Shilpa Medicare targets US approval of 5-HT3 receptor antiemetic for chemotherapy-induced nausea and vomiting (CINV)Phase 3 study met all primary and secondary endpoints, demonstrating superior ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Adding cannabis ...

The effectiveness of a dexamethasone (DEX)-free regimen for chemotherapy-induced nausea and vomiting (CINV) prophylaxis in patients receiving highly emetogenic chemotherapy (HEC) is not known. This ...

As up to 42% of patients with cancer may be using cannabis, one expert spoke to CURE® to separate cannabis myths from reality. Cannabis and cannabinoid access and use among patients with cancer “has ...